DYNACIRC CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC CR is an extended-release oral tablet containing isradipine, a dihydropyridine calcium channel blocker approved in 1994. The drug mechanism and specific indications are not detailed in available data, but calcium channel blockers typically treat hypertension and angina. This product represents an older small-molecule cardiovascular therapy with a mature market presence.
LOE Approaching
Product faces near-term loss of exclusivity with moderate competitive pressure (30/100), indicating a shrinking team and transition planning focus rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Roles available are typically focused on managed decline, generic transition planning, and maximizing remaining exclusivity value rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on DYNACIRC CR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.